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Abstract
Introduction. A slight decrease in blood testosterone level in men is a physiological state associated with the aging. 
The aim of our study was to evaluate the occurrence of hormone and metabolic disorders, as well as the immu-
nolocalization and immunoexpression of androgen receptors (AR) and estrogen-alpha receptors (ERa) in the 
prostates of men with benign prostatic hyperplasia (BPH) and coexisting testosterone deficiency syndrome (TDS).
Material and methods. The study involved 150 men, diagnosed with and receiving pharmacological treatment for 
BPH. Concentrations of glucose, total cholesterol (TCh), high-density lipoproteins (HDL), low-density lipopro-
teins (LDL), and triglycerides (TG) were determined in blood serum. Serum concentrations of total testosterone 
(TT), free testosterone (FT), estradiol (E2), luteinizing hormone (LH), insulin (I), sex hormone-binding globulin 
(SHBG), dehydroepiandrosterone sulfate (DHEAS), and insulin-like growth factor 1 (IGF-1) were measured 
by ELISA. The number of AR-positive cells and ERa-positive cells were measured in prostate sections of men 
with BPH.
Results. Patients eligible for transurethral resection of the prostate and TDS were significantly more likely to have 
higher abdominal circumference and higher serum levels of insulin and IGF-1 as well as lower levels of FT and 
SHBG than control subjects with BPH and no TDS. Quantitative analysis revealed 35.8% AR-positive colum-
nar epithelial cells and 24.3% AR-positive stromal cells in prostates of BPH patients with TDS and 30.5% and 
23.0%, respectively, in BPH patients without TDS. However, the differences between the study and the control 
groups were statistically not significant. In prostates of BPH patients with TDS the immunoexpression of ERa 
was observed in 2.88% of the columnar epithelial cells and 0.39% of stromal cells. In BPH patients without TDS 
ERa-positive cells were only found in 0.04% of columnar epithelial cells and 0.62% of prostatic stromal cells. 
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Conclusions. Considering the statistically significantly higher levels of I and IGF-1 and larger abdominal cir-
cumference of men with BPH and TT deficiency, it can be supposed that visceral obesity and carbohydrate 
disorders may contribute to the reduction of testosterone concentration. The results of our study indicate 
a relationship between TT concentration in the plasma of patients with BPH and the percentage of AR-positive 
cells in the prostate. (Folia Histochemica et Cytobiologica 2015, Vol. 53, No. 3, 227–235)
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Introduction
The development of prostate begins as early as the eight 
week after fertilization, and is determined by testoste-
rone synthesis in the testes. The growth and function 
of the prostate gland are stimulated by dihydrotestoste-
rone (DHT) [1], which acts through androgen receptors 
to induce the expression of the genes associated with 
the synthesis of growth factors [2, 3].
Benign prostatic hyperplasia (BPH) is a commonly 
occurring disease among elderly men. It is character-
ized by the proliferation of epithelial and stromal cells, 
followed by enlargement of the gland [3, 4] leading to 
frequent micturition, difficulties in initiating micturi-
tion, nycturia, a poor stream of urine, and a prolonged 
duration of micturition [4]. BPH can in this way lead 
to lower urinary tract symptoms (LUTS), causing 
a significant decline in the quality of patients’ life [6]. The 
aging of developed societies will result in an increasing 
number of men affected by this problem. Approximate 
data suggests that by the year 2025, about 50 million 
Americans will suffer from BPH symptoms [7], which 
in turn will raise healthcare expenses [8, 9]. 
So far, the etiology of BPH has not been fully ex-
plained [10]. The process of the disease development 
is complex and related to many factors. Currently, we 
know of several etiological factors, of which hormonal 
disorders play an important role [9–12]. Androgens 
are essential for maintaining normal morphology and 
the function of the prostate [12, 13]. Testosterone 
and the product of its enzymatic transformation, di-
hydrotestosterone, undeniably take part in the growth 
and proliferation of prostate cells [14, 15].
A slight decrease in blood testosterone level in 
men is a physiological state associated with the aging. 
However, the decline in the level of testosterone ob-
served in BPH, accompanied by coexisting metabolic 
disorders, is a controversial issue. The aim of our 
research was to assess the occurrence of hormone and 
metabolic disorders, as well as immunolocalization 
and immunoexpression of androgen receptors (AR) 
and estrogen-alpha receptors (ERa), in the prostates 
of men with BPH and coexisting testosterone deficien-
cy syndrome (TDS). 
Material and methods
Patients. The study involved 150 men aged 52–75 years 
(67.33 ± 8.28, mean ± SD), who received pharmacological 
treatment for BPH. The patients were qualified for planned 
transurethral resection of the prostate (TURP) at the Clinic 
of Urology and Urological Oncology at the Pomeranian 
Medical University in Szczecin, Poland.
TDS was diagnosed according to the guidelines of the 
International Society of Andrology (ISA), the Internatio-
nal Society for the Study of the Aging Male (ISSAM), the 
European Association of Urology (EAU), the European 
Academy of Andrology (EAA), and the American Society 
of Andrology (ASA) 2000 [16]. BPH patients with total 
testosterone (TT) level below 2.5 ng/mL, or between 2.5 
and 3.5 ng/mL, having clinical symptoms of ‘low testoster-
one syndrome’ assessed with Morley’s ADAM (Androgen 
Deficiency in Aging Men) questionnaire [17], were classified 
into the group with TDS.
The study group consisted of 54 men diagnosed with 
both BPH and TDS. The control group consisted of 
96 patients with BPH but without TDS, according to the 
above criteria. BPH patients were treated with 5-alpha re-
ductase inhibitor (finasteride, orally, 5 mg daily). Patients 
with active alcoholism, thyroid or liver diseases, and active 
cancerous disease were excluded from the study. 
The study was conducted with the consent of the Bioethi-
cal Commission of Pomeranian Medical University in 
Szczecin (permission number KB-0012/132/12). The patients 
were informed of the purpose and course of the study, and 
gave their written consent to take part in it.
Clinical examination. In both the study and the control 
groups, measurements of abdominal circumference, body 
weight, height, and blood pressure were made. The following 
metabolic parameters in blood serum were determined using 
standard methods: fasting blood glucose levels and the levels 
of total cholesterol (TCh), high-density lipoproteins (HDL), 
low-density lipoproteins (LDL), and triglycerides (TG). 
An enzyme-linked immunosorbent assay (ELISA) method 
was employed to determine the levels of TT, free testosterone 
(FT), estradiol (E2), luteinizing hormone (LH), insulin (I), sex 
hormone-binding globulin (SHBG), dehydroepiandrosterone 
sulfate (DHEAS), and insulin-like growth factor 1 (IGF-1). 
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The patients completed Morley’s ADAM screening 
questionnaire for androgen deficiency in aging males [17]. 
Laboratory measurements. To determine the metabolic 
parameters, 9 mL fasted blood samples were collected from 
a cubital vein. The serum was stored in Eppendorf test tubes 
in a freezer at a temperature of –20°C for no longer than 
three months. The levels of metabolic parameters were 
determined by means of a spectrophotometric method using 
pre-developed assay reagent kits (Biolabo, Aqua-Med, Lodz, 
Poland). Hormone levels were determined with the ELISA 
method using pre-developed assay reagent kits (DRG Med-
tec, Warsaw, Poland). 
Immunohistochemical analysis. To determine the immu-
nolocalization and immunoexpression of AR and ERa in 
the prostates of men with BPH, the prostate sections were 
deparaffinized and hydrated with various concentrations 
of alcohol, in descending order. The sections’ preparations 
were then heated for 30 min in a water bath at a temperature 
of 96°C in Target Retrieval Solution buffer of pH 9.0 (Dako, 
Glostrup, Denmark). Endogenous peroxidase activity was 
blocked with Peroxidase Blocking Solution (Dako) for 
10 min in a humidified chamber at room temperature. The 
sections were incubated for 30 min in a humidified chamber 
with the following monoclonal primary antibodies diluted in 
provided solution (Dako): Monoclonal Mouse Anti-Human 
Androgen Receptor Clone (1:50, Dako) and Monoclonal 
Mouse Anti-Human Estrogen-a Receptor Clone (1:50, 
Dako).
The sections were then incubated with a secondary 
antibody linked to horseradish peroxidase (Dako REAL™ 
EnVision™ Detection System Peroxidase/DAB+, Rabbit/ 
/Mouse, Dako). 5,5’-diaminobenzidine (DAB) was used to 
visualize the immunohistochemical reaction (Dako). The 
sections were counterstained with Mayer’s hematoxylin. 
After each step, the slides were rinsed with phosphate-buf-
fered saline (PBS). The sections were dehydrated and closed 
in the medium Histokitt (Mar-Four, Lodz, Poland). The 
preparations were assessed using a light microscope (BX 
41, Olympus Optical, Tokyo, Japan).
The number of AR-positive cells and ERa-positive cells 
detected by immunohistochemistry were separately count-
ed in prostate sections of patients. Ten fields of vision (at 
a total magnification of ×400) were assessed in 15 section 
for each evaluated prostate of 25 men from the study (BPH 
with TDS) group and 25 men from the control (BPH) group. 
The results were shown as a percentage of AR-positive 
and ERa-positive cells, compared to all stromal cells and 
all columnar epithelial cells of the prostate assessed in the 
field of vision. 
Statistical analysis. Statistical analysis was performed using 
SPSS Statistics 14.0 (Chicago, IL, USA). Basic statistics were 
used for the study and the control groups. The distribution’s 
normality was examined using a Shapiro-Wilk test. Statistical 
analyses were performed using the Mann-Whitney U-test 
and, when appropriate, Student’s t-test. Moreover, the data 
measured on dichotomous scales were analyzed using a chi-
square test of independence with Yates’ correction. Correla-
tions between the parameters were analyzed using Pearson’s 
correlation coefficient. It has been assumed that there was 
no correlation for correlation coefficients of 0.0–0.2, weak 
correlation for 0.2–0.4, moderate correlation for 0.4–0.6, 
strong correlation for 0.6–0.8, and very strong correlation 
for ± 0.8–1.0. The level of significance was set at p < 0.05.
Results
Clinicopathologic characteristics of patients
Data presented in Table 1 show that BPH patients with 
TDS eligible for transurethral resection of the prostate 
were significantly more likely to have higher abdominal 
circumference and serum concentrations of insulin and 
IGF-1, and lower levels of free testosterone and SHBG 
than control BPH patients without TDS.
No statistically significant differences in the fre-
quency of clinically important disorders were found 
between patients with BPH and TDS or BPH patients 
without TDS (Table 2).The mean values of systolic 
and diastolic blood pressure were within normal range 
and did not differ between the study and control 
groups. 
Hypertension was diagnosed according to criteria 
of European Society of Hypertension and European 
Society of Cardiology [18]: systolic blood pressure 
≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg 
or treatment of previously diagnosed hypertension. 
The analysis of the coexisting disorders showed 
that patients with BPH and TDS did not differ from 
patients with BPH and no TDS in respect to the 
incidence of pharmacologically treated hypertension 
(60.32% vs. 55.17%), hypercholesterolemia (33.33% 
vs. 36.78%) or diabetes (28.57% vs. 20.69%).
Serum concentrations of metabolites and hormones
The study group consisted of 54 men with a diagnosis 
of BPH and TDS, and a control group of 96 patients 
with BPH but without TDS. Patients with BPH and 
TDS were significantly more likely to have higher 
abdominal circumference and increased serum levels 
of insulin, IGF-1 and lower levels FT, SHBG than the 
controls with BPH but no TDS (Table 1).
The analysis of data of patients with BPH and with 
TDS demonstrated weak and moderate correlations 
between some parameters (Table 2). Abdominal 
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circumference correlated weakly negatively with 
SGHB level, and the latter correlated weakly nega-
tively with IGF-1 level. Serum glucose concentration 
strongly correlated with serum TG level. The level 
of E2 correlated weakly negatively with the levels of 
TCh and LDL, and positively with the level of FT. 
Serum FT level correlated moderately positively with 
the TT and DHEAS concentrations. We found week 
correlation between TCh and DHEAS levels and 
a negative correlation between IGF-1 and SHBG 
concentrations (Table 2). 
In the group of patients with BPH but without 
TDS (the control group), there was a weak positive 
correlation between abdominal circumference and 
serum levels of IGF-1 and TG (Table 3) and a weak 
negative correlation in respect to SHBG and HDL 
concentrations. Serum glucose concentration corre-
lated weakly negatively with a decrease in the levels 
of LDL, TCh, and FT levels and moderately positively 
with TG concentration. The levels of TG correlated 
weakly positively with IGF-1 concentration and weak-
ly negatively with TT levels. Total testosterone con-
centration correlated weakly with free testosterone 
level and moderately with SHBG concentration. The 
serum level of free testosterone correlated strongly 
with estradiol and moderately with DHEAS concen-
trations. LH level correlated weakly positively with 
SHBG and weakly negatively with IGF-1 concentra-
tions. Insulin levels correlated moderately positively 
with IGF-1 concentrations (Table 3).
Immunohistochemical expression of androgen  
and estrogen-a receptors
The immunohistochemical analysis demonstrated 
differences in the expression of AR and ERa in the 
nuclei of columnar epithelial and stromal cells of pros-
tate between the study group and the control group. 
The microphotographs documenting the expression 
of AR and ERa are shown in Figure 1. 
Table 1. Anthropometric parameters and concentrations of metabolites and hormones in patients with benign prostatic 
hypertrophy (BPH) and testosterone deficiency syndrome (TDS) and with BPH without TDS
Patients with BPH and TDS (n = 54) Patients with BPH and no TDS (n = 96) P value
Mean± SD Range (min–max) Mean± SD Range (min–max)
Age [years] 65.01 ± 6.43 54–75 65.21 ± 6.32 52–75 0.666
Body weight [kg] 87.76 ± 14.44 62–120 81.11 ± 14.54 51.5–165 0.074
Height [cm] 173.58 ± 8.42 153–198 172.82 ± 6.37 154–190 0.895
BMI [kg/m2] 29.15 ± 4.49 18.72–39.18 26.79 ± 3.59 19.15–18.19 0.035
Abdominal circumference [cm] 103.04 ± 9.9 80–123 97.02 ± 8.47 79–125 0.005
Serum concentrations of metabolites and hormones
Glucose (70–100 mg/dL) 117.11 ± 48.74 74–357 106.98 ± 29.62 77–329 0.238
HDL (35–70 mg/dL) 32.96 ± 9.01 20.7–60.27 36.27 ± 10.8 21.43–74.97 0.091
TG (50–200 mg/dL) 163.99 ± 91.32 67.27–609.09 136.13 ± 58.56 57.42–476 0.181
TCh (150–200 mg/dL) 187.08 ± 57.95 83.79–336.43 192.52 ± 59.75 100.75–454.86 0.658
LDL (< 135 mg/dL) 121.32 ± 52.06 18.1–261.01 129.68 ± 58.79 38.99–405.31 0.751
TT (2.6–11 ng/mL) 2.15 ± 0.12 0.09–3.42 5.13 ± 0.14 2.76–8.83 p < 0.01
FT [pg/mL] 68.8 ± 46.5 0.9–247.6 128.5 ± 72.8 20.3–367.6 p < 0.01
LH (2–9 mIU/mL) 11.21 ± 10.42 0.7–67.98 11.12 ± 4.56 3.29–24.99 0.270
SHBG (20–60 nmol/L) 29.6 ± 15.98 2.74–72.91 41.23 ± 19.59 2.58–98.03 p < 0.01
E2 (12–75 pg/mL) 31.08 ± 35.16 5.71–237.71 30.51 ± 25.4 4.93–168.83 0.475
DHEAS (1.1–4.7 μg/mL) 1.23 ± 0.71 0.04–3.44 1.16 ± 0.72 0.12–3.1 0.893
Insulin (15–180 pmol/L) 207.93 ± 175.22 18.47–784.02 116.60 ± 147.23 3.05–698.66 0.002
IGF–1 [ng/mL] 143.13 ± 63.96 41.97–351.1 116.47 ± 35.92 41.58–207.7 0.035
Abbreviations: BPH — benign prostatic hyperplasia, TDS — testosterone deficiency syndrome, BMI — body mass index, HDL — high-density 
lipoprotein, TG — triglycerides, TCh — total cholesterol, LDL — low density lipoprotein, TT — total testosterone, FT — free testosterone,  
E2 — estradiol, LH — luteinizing hormone, I — insulin, SHBG — sex hormone binding globulin, DHEAS — dehydroepiandrosterone sulfate, 
IGF-1 — insulin-like growth factor 1. Laboratory reference values for men are provided in parentheses. Statistically significant differences between 
compared groups were analyzed by Mann-Whitney U-test or Student’s t-test
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The quantitative analysis revealed that patients 
with BPH and TDS did not differ from patients with 
BPH and no TDS in respect to the percentage of 
AR-positive columnar epithelial cells (35.79% vs. 
30.45%) and AR-positive stromal cells (24.32% vs. 
22.98%) of the prostate gland.
There was a weak immunoexpression of the es-
trogen-a receptor in prostate, both in columnar epi-
Table 2. Selected correlations between measured parameters in patients with BPH and diagnosed with TDS
Correlated parameters for 54 subjects Significance Correlation coefficient
Abdominal circumference SHBG 0.016 –0.331
Glucose TG p < 0.01 0.695
Diastolic blood pressure TG 0.028 0.299
Diastolic blood pressure TCh 0.003 0.399
Diastolic blood pressure LDL 0.012 0.341
Diastolic blood pressure FT 0.031 –0.295
TCh E2 0.009 –0.353
LDL E2 0.010 –0.350
TT FT p < 0.01 0.529
FT E2 0.035 0.287
FT DHEAS 0.003 0.403
TCh DHEAS 0.039 0.281
SHBG IGF-1 0.043 –0.366
Abbreviations as in the description of Table 1. Statistical significance was considered at p ≤ 0.05
Table 3. Selected correlations between measured parameters in patients with BPH and no evidence of TDS
Correlated parameters for 96 subjects Significance Correlation coefficient
Abdominal circumference SHBG 0.010 –0.263
Abdominal circumference IGF-1 0.029 0.308
Abdominal circumference TG p < 0.01 0.355
Abdominal circumference HDL 0.027 –0.226
Abdominal circumference Glucose 0.003 0.297
Glucose LDL 0.022 –0.236
Glucose TG p < 0.01 0.471
Glucose FT 0.022 –0.236
Glucose TCh 0.014 –0.254
TG TT 0.050 –0.203
TG IGF-1 0.027 0.312
TT FT 0.002 0.318
TT SHBG p < 0.01 0.488
FT E2 p < 0.01 0.653
FT DHEAS p < 0.01 0.459
LH SHBG 0.007 0.277
LH IGF-1 0.026 –0.316
Insulin IGF-1 0.001 0.534
Abbreviations as in the description of Table 1. Statistical significance was considered at p ≤ 0.05
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thelial cells and stromal cells in the study and control 
groups. In prostates of BPH patients with TDS, the 
immunoreactivity of ERa was observed in 2.88% of 
the columnar epithelial cells and 0.39% of stromal 
cells. In prostates of BPH patients without TDS, 
ERa-positive cells were only found in 0.04% of the 
columnar epithelial cells and 0.62% of stromal cells. 
However, the differences between study and control 
groups were statistically not significant. 
Discussion 
Testosterone deficiency syndrome is associated with 
a decline in androgen serum levels, and may lead to 
numerous clinical symptoms [19]. The most typical 
symptoms include reduction in the sex drive, worsen-
ing of physical and mental state, hair loss, and decline 
of muscle strength and bone mass [20]. 
Our results demonstrate that TDS is a common 
health problem among men with BPH, and that 
hormone and metabolic disorders may differ depend-
ing on testosterone levels. In our study, abdominal 
circumference in patients without TDS correlated 
positively with IGF-1, TG, and glucose levels, but 
such correlations were not observed in patients 
with TDS. A negative correlation between abdom-
inal circumference and SHBG levels was noted 
both in the study and control groups. Analysis of 
the data shows that slight increases in the levels of 
triglycerides, total cholesterol, and LDL, along with 
a decrease in the level of FT, were accompanied by 
an increase in diastolic blood pressure in patients 
with TDS and BPH.
The role of estrogens in the regulation of the male 
reproductive system is increasingly better under-
stood. The peripheral aromatization of testosterone 
is a major source of estrogens in men [21]. With age, 
the serum estradiol level either remains the same 
or increases, resulting in higher ratios of estradiol 
to testosterone [22]. In our study the ratio of E2 to 
TT is 0.07 in study group and 0.17 in control group. 
Investigations on animals confirm that changes in the 
physiological ratio of both hormones contribute to 
a gradual increase in the prostate volume and distur-
bances in urination [23]. Nevertheless, the study of 
Bernoulli et al. [23] fails to confirm the hypothesis that 
a decrease in the ratio of testosterone to estradiol is 
associated with LUTS. However, Tao et al. [24] found 
that patients with BPH had higher estradiol levels 
than patients without BPH. Our results suggest that 
A B
C D
Figure 1. Immunolocalization and immunoexpression of androgen (A, B) and estrogen-a (C, D) receptor in prostate of 
patients with benign prostatic hyperplasia (BPH) and no evidence of testosterone deficiency syndrome (TDS) (A, C) or 
with BPH and TDS (B, D). Weak (A) or strong (B) immunoexpression in the nuclei of columnar epithelial cells (black 
arrow) and in the stromal cells (red arrow). Lack of immunoexpression of estrogen-a receptor in cell nuclei (C), and 
immunoreactivity present in several nuclei of columnar epithelial cells (black arrow) (D); scale bar — 20 μm
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there is a relationship between the levels of estradiol 
and FT, both in BPH patients with and without TDS. 
In our study, a positive moderate correlation 
between the levels of DHEAS and FT was found in 
both the study and control groups. This may be caused 
by the fact that both DHEA and DHEAS can be 
substrates in the process of biosynthesis of estrogen 
and testosterone [24]. Schatzl et al. [25] analyzed the 
relationships between hormone levels depending on 
the malignancy of pathological changes in the pros-
tate. The levels of estradiol in this study were lower 
in patients with prostate tumors than in those with 
BPH/LUTS. However, no significant relationships 
between the levels of DHEAS and testosterone in 
both groups were found. 
Insulin-like growth factor 1 (IGF-1) is a sin-
gle-chain polypeptide hormone that can influence the 
growth, differentiation, and survival of cells. There is 
a hypothesis that IGF-1, which is structurally similar 
to insulin, may bind the same receptors and activate 
pathways implicated in the growth and proliferation 
of prostate cells. Moreover, some studies imply that 
elevated blood insulin levels are associated with 
higher activity of the sympathetic nervous system, and 
may increase prostate smooth muscle tension [26]. An 
in vitro study by Siejka et al. [27] demonstrated that 
pharmacological blockade of the action of growth 
factors may suppress the proliferation of human 
BPH cells. 
The immunohistochemical results presented here 
show that AR-positive cell nuclei are more often 
found in the columnar epithelial cells and stromal 
cells of BPH patients with TDS than in BPH patients 
without TDS. The assessment of ERa immunoexpres-
sion reveals that the much higher incidence of these 
receptors is found in the columnar epithelial prostatic 
cells of men with BPH and TDS than in BPH patients 
without TDS. 
There are many theories which prove the influence 
of testosterone and differences in AR expression in 
BPH. In normal prostate and BPH specimens AR are 
located in the nuclei of luminal epithelial cells, stromal 
cells, and basal epithelial cells [28]. Testosterone and 
other androgens as well as AR are important prostatic 
growth factors. They are necessary for maintenance 
of normal structure of prostate and were found to 
stimulate epithelial proliferation in castrated ani-
mals. Prostatic over-expression of epithelial AR in 
an animal model increased cellular proliferation 
[29]. There are also reports about growth-promoting 
role of AR and testosterone. Loss of AR-positive 
epithelial cells in conditional knockout animals and 
tissue recombinants results in increased epithelial 
proliferation and inhibition of prostate differentiation 
[30, 31]. The recent study of Wen et al. [32] showed 
that androgen receptors located in the prostate 
stroma may take part in the etiology of BPH. The 
immunohistochemical analysis of androgen receptors 
in BPH patients treated with finasteride conducted by 
Bauman et al. [33] suggests that this treatment may 
decrease the expression of this receptor in the prostate 
epithelium. Biolchi et al. [34] analyzed genotypes and 
testosterone levels in a group of 126 patients, aged 
40 to 60 years, whose prostate volumes exceeded 
30 mL. They demonstrated that the presence of a high 
number of repetitions of GGC in the gene encoding 
AR, as well as a lower testosterone level, predispose 
to a higher risk of BPH. 
Estrogen-alpha receptors act comprehensively in 
both the female and male reproductive systems [35]. It 
has been suggested that the development of BPH in 
men may be related to the direct action of estradiol, 
e.g. due to the aromatization of androgens to estro-
gens which then bind to ERs in prostate and bladder 
[36]. This hypothesis was analyzed in men older than 
40 years with BPH and other LUTS by Schatzl et 
al. [37] who showed that increased estrogens levels 
correlated closely with prostate hyperplasia, while 
increased serum testosterone level did not. There are 
reports on the activity of selective ER modulators, 
which in vivo reduced proliferation of human prosta - 
tic cells and initiated apoptosis and anti-inflammatory 
processes [38]. The results of these studies underline 
the special role of ERs as factors that are potentially 
important in BPH therapy [39]. However, the role of 
E2 in the prostate is not clear. Prins et al. suggested 
that estrogen imprinting and prostate pathologies 
are mediated by ERa of the stromal cells [40]. In 
normal prostatic cells ERa is found primarily in the 
nuclei of stromal cells; however, ERa is also found 
in epithelial cells [41]. The studies of Ricke et al. 
showed that in estrogen-treated male mice, the num-
ber of ERa-positive cells in the prostatic epithelium 
increased, while the number of ERa-positive epi-
thelial cells decreased. This suggests that estrogens 
may mediate proliferation of prostatic epithelium. 
ERa is necessary for the proliferation of prostatic 
cells in estrogen-treated mice [41]. Thus, the role of 
E2 in BPH remains to be elucidated. 
Determining the relationship between BPH and 
TSD, changes the levels of other hormones, meta-
bolic disorders could have important therapeutic 
implications for the treatment of diseases of aging 
in men. Considering the higher levels of insulin and 
IGF-1 and larger abdominal circumference of men 
with BPH and TDS, it can be supposed that visceral 
obesity and carbohydrate disorders may contribute to 
the reduction of serum testosterone concentration. 
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